Evaluating strategies to improve rotavirus vaccine impact during the second year of life in Malawi

Virginia E. Pitzer, Aisleen Bennett, Naor Bar-Zeev, Khuzwayo C. Jere, Benjamin A. Lopman, Joseph A. Lewnard, Umesh D. Parashar, Nigel A. Cunliffe

Research output: Contribution to journalArticle

Abstract

Rotavirus vaccination has substantially reduced the incidence of rotavirus-associated gastroenteritis (RVGE) in high-income countries, but vaccine impact and estimated effectiveness are lower in low-income countries for reasons that are poorly understood. We used mathematical modeling to quantify rotavirus vaccine impact and investigate reduced vaccine effectiveness, particularly during the second year of life, in Malawi, where vaccination was introduced in October 2012 with doses at 6 and 10 weeks. We fitted models to 12 years of prevaccination data and validated the models against postvaccination data to evaluate the magnitude and duration of vaccine protection. The observed rollout of vaccination in Malawi was predicted to lead to a 26 to 77% decrease in the overall incidence of moderate-to-severe RVGE in 2016, depending on assumptions about waning of vaccine-induced immunity and heterogeneity in vaccine response. Vaccine effectiveness estimates were predicted to be higher among 4- to 11-month-olds than 12- to 23-month-olds, even when vaccine-induced immunity did not wane, due to differences in the rate at which vaccinated and unvaccinated individuals acquire immunity from natural infection. We found that vaccine effectiveness during the first and second years of life could potentially be improved by increasing the proportion of infants who respond to vaccination or by lowering the rotavirus transmission rate. An additional dose of rotavirus vaccine at 9 months of age was predicted to lead to higher estimated vaccine effectiveness but to only modest (5 to 16%) reductions in RVGE incidence over the first 3 years after introduction, regardless of assumptions about waning of vaccine-induced immunity.

Original languageEnglish (US)
Article numbereaav6419
JournalScience translational medicine
Volume11
Issue number505
DOIs
StatePublished - Aug 14 2019

Fingerprint

Rotavirus Vaccines
Malawi
Vaccines
Rotavirus
Gastroenteritis
Vaccination
Immunity
Incidence
Innate Immunity

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pitzer, V. E., Bennett, A., Bar-Zeev, N., Jere, K. C., Lopman, B. A., Lewnard, J. A., ... Cunliffe, N. A. (2019). Evaluating strategies to improve rotavirus vaccine impact during the second year of life in Malawi. Science translational medicine, 11(505), [eaav6419]. https://doi.org/10.1126/scitranslmed.aav6419

Evaluating strategies to improve rotavirus vaccine impact during the second year of life in Malawi. / Pitzer, Virginia E.; Bennett, Aisleen; Bar-Zeev, Naor; Jere, Khuzwayo C.; Lopman, Benjamin A.; Lewnard, Joseph A.; Parashar, Umesh D.; Cunliffe, Nigel A.

In: Science translational medicine, Vol. 11, No. 505, eaav6419, 14.08.2019.

Research output: Contribution to journalArticle

Pitzer, VE, Bennett, A, Bar-Zeev, N, Jere, KC, Lopman, BA, Lewnard, JA, Parashar, UD & Cunliffe, NA 2019, 'Evaluating strategies to improve rotavirus vaccine impact during the second year of life in Malawi', Science translational medicine, vol. 11, no. 505, eaav6419. https://doi.org/10.1126/scitranslmed.aav6419
Pitzer, Virginia E. ; Bennett, Aisleen ; Bar-Zeev, Naor ; Jere, Khuzwayo C. ; Lopman, Benjamin A. ; Lewnard, Joseph A. ; Parashar, Umesh D. ; Cunliffe, Nigel A. / Evaluating strategies to improve rotavirus vaccine impact during the second year of life in Malawi. In: Science translational medicine. 2019 ; Vol. 11, No. 505.
@article{27129ab644114ce6aa410d62348dbed1,
title = "Evaluating strategies to improve rotavirus vaccine impact during the second year of life in Malawi",
abstract = "Rotavirus vaccination has substantially reduced the incidence of rotavirus-associated gastroenteritis (RVGE) in high-income countries, but vaccine impact and estimated effectiveness are lower in low-income countries for reasons that are poorly understood. We used mathematical modeling to quantify rotavirus vaccine impact and investigate reduced vaccine effectiveness, particularly during the second year of life, in Malawi, where vaccination was introduced in October 2012 with doses at 6 and 10 weeks. We fitted models to 12 years of prevaccination data and validated the models against postvaccination data to evaluate the magnitude and duration of vaccine protection. The observed rollout of vaccination in Malawi was predicted to lead to a 26 to 77{\%} decrease in the overall incidence of moderate-to-severe RVGE in 2016, depending on assumptions about waning of vaccine-induced immunity and heterogeneity in vaccine response. Vaccine effectiveness estimates were predicted to be higher among 4- to 11-month-olds than 12- to 23-month-olds, even when vaccine-induced immunity did not wane, due to differences in the rate at which vaccinated and unvaccinated individuals acquire immunity from natural infection. We found that vaccine effectiveness during the first and second years of life could potentially be improved by increasing the proportion of infants who respond to vaccination or by lowering the rotavirus transmission rate. An additional dose of rotavirus vaccine at 9 months of age was predicted to lead to higher estimated vaccine effectiveness but to only modest (5 to 16{\%}) reductions in RVGE incidence over the first 3 years after introduction, regardless of assumptions about waning of vaccine-induced immunity.",
author = "Pitzer, {Virginia E.} and Aisleen Bennett and Naor Bar-Zeev and Jere, {Khuzwayo C.} and Lopman, {Benjamin A.} and Lewnard, {Joseph A.} and Parashar, {Umesh D.} and Cunliffe, {Nigel A.}",
year = "2019",
month = "8",
day = "14",
doi = "10.1126/scitranslmed.aav6419",
language = "English (US)",
volume = "11",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "505",

}

TY - JOUR

T1 - Evaluating strategies to improve rotavirus vaccine impact during the second year of life in Malawi

AU - Pitzer, Virginia E.

AU - Bennett, Aisleen

AU - Bar-Zeev, Naor

AU - Jere, Khuzwayo C.

AU - Lopman, Benjamin A.

AU - Lewnard, Joseph A.

AU - Parashar, Umesh D.

AU - Cunliffe, Nigel A.

PY - 2019/8/14

Y1 - 2019/8/14

N2 - Rotavirus vaccination has substantially reduced the incidence of rotavirus-associated gastroenteritis (RVGE) in high-income countries, but vaccine impact and estimated effectiveness are lower in low-income countries for reasons that are poorly understood. We used mathematical modeling to quantify rotavirus vaccine impact and investigate reduced vaccine effectiveness, particularly during the second year of life, in Malawi, where vaccination was introduced in October 2012 with doses at 6 and 10 weeks. We fitted models to 12 years of prevaccination data and validated the models against postvaccination data to evaluate the magnitude and duration of vaccine protection. The observed rollout of vaccination in Malawi was predicted to lead to a 26 to 77% decrease in the overall incidence of moderate-to-severe RVGE in 2016, depending on assumptions about waning of vaccine-induced immunity and heterogeneity in vaccine response. Vaccine effectiveness estimates were predicted to be higher among 4- to 11-month-olds than 12- to 23-month-olds, even when vaccine-induced immunity did not wane, due to differences in the rate at which vaccinated and unvaccinated individuals acquire immunity from natural infection. We found that vaccine effectiveness during the first and second years of life could potentially be improved by increasing the proportion of infants who respond to vaccination or by lowering the rotavirus transmission rate. An additional dose of rotavirus vaccine at 9 months of age was predicted to lead to higher estimated vaccine effectiveness but to only modest (5 to 16%) reductions in RVGE incidence over the first 3 years after introduction, regardless of assumptions about waning of vaccine-induced immunity.

AB - Rotavirus vaccination has substantially reduced the incidence of rotavirus-associated gastroenteritis (RVGE) in high-income countries, but vaccine impact and estimated effectiveness are lower in low-income countries for reasons that are poorly understood. We used mathematical modeling to quantify rotavirus vaccine impact and investigate reduced vaccine effectiveness, particularly during the second year of life, in Malawi, where vaccination was introduced in October 2012 with doses at 6 and 10 weeks. We fitted models to 12 years of prevaccination data and validated the models against postvaccination data to evaluate the magnitude and duration of vaccine protection. The observed rollout of vaccination in Malawi was predicted to lead to a 26 to 77% decrease in the overall incidence of moderate-to-severe RVGE in 2016, depending on assumptions about waning of vaccine-induced immunity and heterogeneity in vaccine response. Vaccine effectiveness estimates were predicted to be higher among 4- to 11-month-olds than 12- to 23-month-olds, even when vaccine-induced immunity did not wane, due to differences in the rate at which vaccinated and unvaccinated individuals acquire immunity from natural infection. We found that vaccine effectiveness during the first and second years of life could potentially be improved by increasing the proportion of infants who respond to vaccination or by lowering the rotavirus transmission rate. An additional dose of rotavirus vaccine at 9 months of age was predicted to lead to higher estimated vaccine effectiveness but to only modest (5 to 16%) reductions in RVGE incidence over the first 3 years after introduction, regardless of assumptions about waning of vaccine-induced immunity.

UR - http://www.scopus.com/inward/record.url?scp=85071281268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071281268&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.aav6419

DO - 10.1126/scitranslmed.aav6419

M3 - Article

C2 - 31413144

AN - SCOPUS:85071281268

VL - 11

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 505

M1 - eaav6419

ER -